Cardiovascular
Real-World Applicability of Anti-VEGF Trial Criteria for Diabetic Macular Edema.
- Journal
- American journal of ophthalmology
- Published
- December 4, 2026
- Source
- PubMed / NLM
- Credibility
- 80 / 100
Key takeaway
Clinical trials for diabetes-related vision loss treatments exclude Black adults at roughly twice the rate of white patients due to strict health rules. This matters because it means these common eye medicines aren’t being properly tested on our community. To ensure treatments are safe and effective for us, research must reflect real-world health needs.
Why this matters for our communities
Research in cardiovascular helps close long-standing gaps in how Black and African American families are studied, diagnosed, and cared for. Use findings like this one to start informed conversations with your care team — not as a substitute for personal medical advice.
More in Cardiovascular
January 23, 2027Artificial Intelligence in Aortic Disease: From Imaging to Personalized Medicine.Read January 21, 2027Enhanced Blood Suppression in Magnetic Resonance Vessel Wall Imaging Using Toggled DANTE (tDANTE).Read January 15, 2027Cardiometabolic Health and Risk of Breast Cancer Subtypes Among US Black Women.Read
